个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Pu Xingxiang[1] * ; Xu Chunwei[2,3] * ; Wang Qian[4] * ; Wang Wenxian[5] * ; Wu Fang[6] * ; Cai Xiuyu[7] ; Song Zhengbo[5] ; Yu Jinpu[8] ; Zhong Wenzhao[9] ; Wang Zhijie[10] ; Zhang Yongchang[11] ; Liu Jingjing[12] ; Zhang Shirong[13] ; Liu Anwen[14] ; Li Wen[15] ; Zhan Ping[3] ; Liu Hongbing[3] ; Lv Tangfeng[3] ; Miao Liyun[16] ; Min Lingfeng[17] ; Lin Gen[18] ; Huang Long[14] ; Yuan Jingping[19] ; Jiang Zhansheng[20] ; Rao Chuangzhou[21] ; Lv Dongqing[22] ; Yu Zongyang[23] ; Li Xiaoyan[24] ; Tang Chuanhao[25] ; Zhou Chengzhi[26] ; Zhang Junping[27] ; Guo Hui[28] ; Chu Qian[29] ; Meng Rui[30] ; Liu Xuewen[31] ; Wu Jingxun[32] ; Zhou Jin[33] ; Zhu Zhengfei[34] ; Pan Weiwei[35] ; Pang Fei[36] ; Huang Jintao[36] ; Wang Kai[36] ; Wu Fan[37] ; Shen Tingting[38] ; Zou Shirui[38] ; Xu Bingwei[39] ; Wang Liping[40] ; Zhu Youcai[41] ; Lin Xinqing[26] ; Cai Jing[14] ; Xu Ling[42] ; Li Jisheng[43] ; Jiao Xiaodong[44] ; Li Kainan[45] ; Feng Huijing[27] ; Wang Lin[46] ; Du Yingying[47] ; Yao Wang[48] ; Shi Xuefei[49] ; Niu Xiaomin[50] ; Yuan Dongmei[3] ; Yao Yanwen[3] ; Kang Jing[9] ; Zhang Jiatao[9] ; Zhang Chao[9] ; Fu Jianfei[51] ; Huang Jianhui[52] ; Zhang Yinbin[53] ; Sun Pingli[54] ; Wang Hong[55] ; Ye Mingxiang[3] ; Wang Dong[3] ; Wang Zhaofeng[3] ; Hao Yue[5] ; Wang Zhen[56] ; Wan Bing[57] ; Lv Donglai[58] ; Lan Gang[41] ; Yang Shengjie[59] ; Shi Lin[60] ; Wang Yina[61] ; Li Bihui[62] ; Zhang Zhang[63] ; Li Zhongwu[64] ; Li Yuan[65] ; Liu Zhefeng[55] ; Yang Nong[11] ; Wang Huijuan[66] ; Huang Wenbin[67] ; Hong Zhuan[68] ; Wang Guansong[69] ; Wang Jiandong[70] ; Fang Meiyu[5] ; Fang Yong[71] ; Zhu Xixu[56] ; Shen Yi[72] ; Zhang Yiping[5] ; Ma Shenglin[73] ; Song Yong[3] ; Lu Yuanzhi[74] ; Fang Wenfeng[75] ; Li Ziming[50] ; Wu Lin[1,*1] ;
机构： [1]The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Central South University, Changsha, People’s Republic of China [2]Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, People’s Republic of China [3]Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, People’s Republic of China [4]Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, People’s Republic of China [5]Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, People’s Republic of China [6]Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, People’s Republic of China [7]Department of VIP Inpatient, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China [8]Department of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China [9]Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, People’s Republic of China [10]State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China [11]Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China [12]Department of Thoracic Cancer, Jilin Cancer Hospital, Jilin, People’s Republic of China [13]Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China [14]Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China [15]Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, People’s Republic of China [16]Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, People’s Republic of China [17]Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People’s Hospital of Jiangsu Province, Yangzhou, People’s Republic of China [18]Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, People’s Republic of China [19]Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China [20]Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China [21]Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, People’s Republic of China [22]Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, People’s Republic of China [23]Department of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou, People’s Republic of China [24]Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China [25]Department of Medical Oncology, Peking University International Hospital, Beijing, People’s Republic of China [26]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease [27]Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University (The First Affiliated Hospital of Guangzhou Medical University), Guangzhou, People’s Republic of China [28]Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, People’s Republic of China [29]Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China [30]Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China [31]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China [32]Department of Oncology, the Third Xiangya Hospital, Central South University, Changsha, People’s Republic of China [33]Department of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen, People’s Republic of China [34]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology, Chengdu, People’s Republic of China [35]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China [36]Department of Cell Biology, College of Medicine, Jiaxing University, Jiaxing, People’s Republic of China [37]Department of Medical, Shanghai OrigiMed Co, Ltd, Shanghai, People’s Republic of China [38]Department of Medical, Menarini Silicon Biosystems Spa, Shanghai, People’s Republic of China [39]Department of Medical, Stone Pharmaceuticals (Suzhou) Co., Ltd., Shanghai, People’s Republic of China [40]Department of Biotherapy, Cancer Institute, First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China [41]Department of Oncology, Baotou Cancer Hospital, Baotou, People’s Republic of China [42]Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, People’s Republic of China [43]Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei, People’s Republic of China [44]Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinnan, People’s Republic of China [45]Department of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, People’s Republic of China [46]Department of Oncology, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China [47]Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, People’s Republic of China [48]Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China [49]Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China [50]Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, People’s Republic of China [51]Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China [52]Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China [53]Department of Oncology, Lishui Municipal Central Hospital, Lishui, People’s Republic of China [54]Department of Oncology, the Second Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, People’s Republic of China [55]Department of Pathology, The Second Hospital of Jilin University, Changchun, People’s Republic of China [56]Senior Department of Oncology, The 5th Medical Center of PLA General Hospital, Beijing, People’s Republic of China [57]Department of Radiation Oncology, Affiliated Jinling Hospital, Medical School of Nanjing, Nanjing, People’s Republic of China [58]Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, People’s Republic of China [59]Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei, People’s Republic of China [60]Department of Thoracic Surgery, Chuxiong Yi Autonomous Prefecture People’s Hospital, Chuxiong, People’s Republic of China [61]Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China [62]Department of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China [63]Department of Oncology, The Second Affiliated Hospital of Guilin Medical University, Guilin, People’s Republic of China [64]International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou, People’s Republic of China [65]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China [66]Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China [67]Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People’s Republic of China [68]Department of Pathology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang, People’s Republic of China [69]Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, People’s Republic of China [70]Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, People’s Republic of China [71]Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, People’s Republic of China [72]Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, People’s Republic of China [73]Department of Thoracic Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, People’s Republic of China [74]Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China [75]Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, People’s Republic of China [76]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China
出处：
DOI： 10.1111/1759-7714.15105
ISSN：

关键词： NSCLC precision medicine RET fusion targeted therapy tyrosine receptor kinase

摘要：
The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell-surface molecules responsible for transmitting signals that regulate cell growth and differentiation. In non-small cell lung cancer (NSCLC), RET fusion is a rare driver gene alteration associated with a poor prognosis. Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles. These inhibitors have shown the ability to overcome resistance to multikinase inhibitors (MKIs). Furthermore, ongoing clinical trials are investigating several second-generation sRETis that are specifically designed to target solvent front mutations, which pose a challenge for first-generation sRETis. The effective screening of patients is the first crucial step in the clinical application of RET-targeted therapy. Currently, four methods are widely used for detecting gene rearrangements: next-generation sequencing (NGS), reverse transcription-polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC). Each of these methods has its advantages and limitations. To streamline the clinical workflow and improve diagnostic and treatment strategies for RET fusion NSCLC, our expert group has reached a consensus. Our objective is to maximize the clinical benefit for patients and promote standardized approaches to RET fusion screening and therapy.© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

基金：
This work was supported by the Science and Technology Innovation Program of Hunan Province (grant number 2023SK4024), the Natural Science Foundation of China (grant number 82002456), China Postdoctoral Science Foundation (grant number 2022M723207), and the Medical Scientific Research Foundation of Zhejiang Province of China (grant number 2023KY666).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
JCR分区：
出版当年[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY
最新[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Central South University, Changsha, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构： [1]The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Central South University, Changsha, People’s Republic of China [*1]The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha Hunan 410 013, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Pu Xingxiang,Xu Chunwei,Wang Qian,et al.Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China[J].Thoracic Cancer.2023,14(31):3166-3177.doi:10.1111/1759-7714.15105.
APA：
Pu Xingxiang,Xu Chunwei,Wang Qian,Wang Wenxian,Wu Fang...&Wu Lin.(2023).Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.Thoracic Cancer,14,(31)
MLA：
Pu Xingxiang,et al."Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China".Thoracic Cancer 14..31(2023):3166-3177

相关文献

[1]Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China [2]Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors [3]Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors [4]Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer [5]AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. [6]骨肉瘤中Axl抑制凋亡及与凋亡蛋白的相关性 [7]表皮生长因子受体酪氨酸激酶抑制剂ZD1839对鼻咽癌细胞系的作用 [8]mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. [9]Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway) [10]Synergistic effect of canakinumab with epidermal growth factor receptor tyrosine kinase inhibitors versus with chemotherapy for non-small cell lung cancer

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号